Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
CHOLEDYL (oxtriphylline) is an oral solution bronchodilator in pre-launch development by Pfizer. Oxtriphylline is a xanthine derivative used to treat respiratory conditions by relaxing airway smooth muscle. The drug targets patients with obstructive airway disease requiring oral maintenance therapy.
Pre-launch stage indicates early commercial planning and team building for market entry; significant opportunity for launch-focused roles.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CHOLEDYL at pre-launch offers early-stage career visibility and influence on product positioning before market entry. Team size and opportunity are likely growing as Pfizer prepares launch infrastructure.
Worked on CHOLEDYL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.